Treatment of non-small-cell lung cancer with prolonged oral etoposide

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 505-508

  Kakolyris, S ^a,b   Samonis, G ^a   Koukourakis, M ^a   Vlachonicolis, I ^a   Chalkiadakis, G ^a   Kalbakis, K ^a   Souglakos, I ^a   Agelaki, S ^a   Toloudis, P ^a   Georgoulias, V ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Etoposide; Non small cell lung cancer; Oral chemotherapy

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0031753296     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00018     Document Type: Article

References (18)

1. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997;858-910.
2. Walling J. Chemotherapy for advanced non-small cell lung cancer. Respir Med 1994;88:649-57.
3. Kris MG. Mitomycin in combination chemotherapy regimens for patients with advanced non-small cell lung cancer. In: Gralla RJ, Einhorn LH, eds. Treatment and prevention of small cell lung cancer and non small cell lung cancer. New York: Royal Society of Medicine, 1989;101-9.
4. Drings P. Ifosfamide in the treatment of bronchial carcinoma. In: Brade WB, Nagel EA, Seeber S, eds. Ifosfamide in tumour therapy. New York: Karger, 1987;294-318.
5. Bunn PA Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989;16(suppl 4):10-21.
6. Giaccone G. New drugs in non-small cell lung cancer. an overview. Lung Cancer 1995;12(suppl 1):155-62.
7. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Vogel S. A randomised trial of four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
8. Byrne A, Carney DN. Cancer in the elderly. In: Ozds RF, Steele G Jr, Kinsella TJ, eds. Current problems in cancer. St. Louis: Mosby, 1993;145-220.
9. Van Maaner JVS, Retel J, Pinedo HM. Mechanisms of action of antitumour drug etoposide: a review. J Natl Cancer Inst 1988;80:1526-33.
10. Stewart JD, Nundy D, Maroun AJ, Tetreault L, Drior J. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 1985;69:269-73.
11. Slevin ML, Joel SP, Etoposide. In: Cvitkovitc E, Droz JP, Armand JP, Khoury S, eds. Handbook of chemotherapy in clinical oncology. Jersey, Channel Islands: Scientific Communication International Ltd, 1993;334-7.
12. Saxman S, Loehrer PJ, Logie K, et al. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Invest New Drugs 1991;9:253-6.
13. Estapé J, Palombo H, Sanchez-Lloret J, et al. Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 1992;28A:835-7.
14. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA. Prolonged administration of oral etoposide in small-cell lung cancer: a phase II trial. J Clin Oncol 1992;10:292-6.
15. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization offset publication No. 48, 1979.
16. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Boston: Blackwell Scientific Publications, 1990.
17. Kaplan EL, Meir P. Non parametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.
18. Smith IE. Palliative chemotherapy for advanced non-small cell lung cancer: time to reappraise its role. BMJ 1994;308:429-30.